Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The CMS study will include diverse and rural seniors to ensure robust Medicare data in populations traditionally underrepresented.
People ages 6 months and older are eligible for new Moderna and Pfizer-BioNTech boosters targeting XBB.1.5 omicron variant.
The efficacy of Zurzuvae was demonstrated in two randomized, placebo-controlled, multicenter studies.
The fast-acting gel, which stimulates nerve endings in the penis, produces an erection in about 10 minutes.
Arexvy RSV vaccine is now approved for individuals age 60 and older.
Newly FDA-approved drugs for ovarian, bladder, liver cancer, and more.
The Dana-Farber led ALPINE trial looked at the drug in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Mosunetuzumab is the first bispecific antibody, a type of immunotherapy, approved to treat non-Hodgkin lymphoma.
Rezlidhia (olutasidenib) is approved as a targeted treatment option for adults whose acute myeloid leukemia carries the IDH1 mutation.
Krazati led to tumor shrinkage in 43% of previously treated NSCLC patients with KRAS G12C mutations.
Updated Pfizer-BioNTech and Moderna bivalent boosters contain spike proteins from the original and BA.4 and BA.5 omicron variants.
Elahere, a new antibody-drug conjugate, shrank tumors in about a third of treatment-experienced patients.
The engineered protein vaccine was highly effective in a clinical trial but faced a long delay for authorization.
Azacitidine (Vidaza) was approved for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML).
The potentially lifesaving prescription drug buprenorphine is less available to women and Black and Latino people with opioid addiction.
Remdesivir (Veklury) is now approved for kids ages 28 days to 12 years.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.